Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.
The research group led by Dr Sjoerd van Wijk from the Institute of Experimental Cancer Research in Paediatrics at Goethe University already two years ago found evidence indicating that the anti-diarrhea drug loperamide could be used to induce cell death in glioblastoma cell lines.
One of the hallmarks of Glioblastoma (GBM), the most aggressive type of brain cancer, is its high invasive capacity, which leads to its expansion into the normal brain tissue.
Researchers at Tel Aviv University have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers.
Scientists have designed a new targeted therapy, known as POMHEX, which inhibits vital metabolic pathways in tumor cells containing specific genetic defects.
Researchers have shown that the advanced CRISPR/Cas9 system is extremely effective in curing metastatic cancers.
Researchers have designed a laboratory test that can precisely examine the deadliest cells found in the most common and aggressive type of brain cancer.
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.
New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma.
The multiplication of genes located in extrachromosomal DNA that have the potential to cause cancer drives poor patient outcomes across many cancer types, according to a Nature Genetics study published Aug. 17, 2020 by a team of researchers including Professors Vineet Bafna and Dr.Paul Mischel of the University of California San Diego and Professor Roel Verhaak of Jackson Laboratories.
More than 200 genes with novel and known roles in glioblastoma - the most aggressive type of brain cancer - offer promising new drug targets.
Scientists keen on solving the regulation of genes implicated in human health and disease are widening their horizons by closely APA.
Therapies for treating glioblastoma brain cancer can be delivered with greater precision and existing drugs can be used in new ways.
Scientists have identified an oncogene (a cancer-causing gene) responsible for glioblastoma, the deadliest brain tumor.
A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.
By sequencing entire genomes for DNA modifications, and analyzing both cancer tissues and healthy ones, Hackensack Meridian Health researchers and doctors have found what could be a key to risks for cancer and other diseases: specific locations in the DNA where those expression changes (methylation) are imbalanced, according to a new publication.
A novel molecule LIH383 developed by scientists at the Luxembourg Institute of Health binds to and inhibits a formerly unknown opioid receptor in the brain.
Researchers have developed a new approach to identify functional mutations and their impact on genes applicable to the development of malignant brain tumors.
Lung cancers account for approximately 25 percent of all cancer deaths. Even among those who do not smoke, 1 in 15 men and 1 in 17 women are expected to develop lung cancer in their lifetime, according to the American Cancer Society.